A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 355-364

  Stellrecht, Christine M ^a   Ayres, Mary ^a   Arya, Rishi ^a   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

8 chloro adenosine; Breast cancer; Cyclin E; Nucleoside analog; RNA synthesis inhibition

Indexed keywords

8 CHLOROADENOSINE 3',5' PHOSPHATE; ADENOSINE TRIPHOSPHATE; CYCLIN E; NUCLEOSIDE ANALOG; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RNA; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENICITY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; DRUG UPTAKE; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RNA SYNTHESIS; TRANSCRIPTION REGULATION;

2-CHLOROADENOSINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIN E; FEMALE; FLOW CYTOMETRY; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 77953027504     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0481-3     Document Type: Article

References (54)

1. Stellrecht CM, Chen LS, Gandhi V (2005) Inhibition of oncogene expression by RNA-directed agents. In: Gandhi V (ed) Transcription as a target for cancer therapeutics AACR educational book. American Association for Cancer Research, Philadelphia, pp 338-343
2. Derheimer FA, Chang CW, Ljungman M (2005) Transcription inhibition: a potential strategy for cancer therapeutics. Eur J Cancer 41:2569-2576 (Pubitemid 41540631)
3. Bakheet T, Williams BR, Khabar KS (2003) ARED 2.0: an update of AU-rich element mRNA database. Nucleic Acids Res 31:421-423 (Pubitemid 36150418)
4. Lam LT, Pickeral OK, Peng AC et al. (2001) Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2:research0041. 0041-research0041.0011
5. Weinstein IB (2002) Addiction to oncogenes-the Achilles heal of cancer. Science 297:63-64
6. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68: 3077-3080
7. Weinstein B (2008) Relevance of the concept of oncogene addiction to hormonal carcinogenesis and molecular targeting in cancer prevention and therapy. Adv Exp Med Biol 6.1.7:3-13
8. Certo M, Moore Vdel G, Nishino M et al (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351-365 (Pubitemid 43668734)
9. Chen R, Wierda WG, Chubb S et al (2009) Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 1134637-1134645 doi:10.1182/blood-2008-12-190256
10. Chen R, Keating MJ, Gandhi V, Plunkett W (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106:2513-2519 (Pubitemid 41510827)
11. Gojo I, Zhang B, Fenton RG (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8:3527-3538 (Pubitemid 35340731)
12. Pepper C, Thomas A, Hoy T, Fegan C, Bentley P (2001) Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol 114:70-77 (Pubitemid 32702635)
13. Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V (2009) Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol 63:587-597. doi: 10.1007/s00280-008-0770-2
14. Raje N, Kumar S, Hideshima T et al (2005) Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106:1042-1047 (Pubitemid 41076452)
15. MacCallum DE, Melville J, Frame S et al (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65:5399-5407 (Pubitemid 40827353)
16. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770-1783 (Pubitemid 46628473)
17. Balakrishnan K, Stellrecht CM, Genini D et al (2005) Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood 1054455-1054462 doi: 10.1182/blood-2004-05-1699
18. Langeveld CH, Jongenelen CA, Theeuwes JW et al (1997) The antiproliferative effect of 8-chloro-adenosine, an active metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell cycle kinetics. Biochem Pharmacol 53:141-148. doi:S0006-2952(96)00593-X[p.ii]
19. Langeveld CH, Jongenelen CA, Heimans JJ, Stoof JC (1992) 8-Chloro-cyclic adenosine monophosphate, a novel cyclic AMP analog that inhibits human glioma cell growth in concentrations that do not induce differentiation. Exp Neurol 117:196-203. doi:001.4-4886(92)90127-C[pii]
20. Langeveld CH, Jongenelen CA, Heimans JJ, Stoof JC (1992) Growth inhibition of human glioma cells induced by 8-chloroadenosine, an active metabolite of 8-chloro cyclic adenosine 3′:5′-monophosphate. Cancer Res 52:3994-3999
21. Gandhi V, Ayres M, Halgren RG et al (2001) 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res 61:5474-5479 (Pubitemid 32694929)
22. Krett NL, Zell JL, Halgren RG et al (1997) Cyclic adenosine-3′, 5′-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. Clin Cancer Res 3:1781-1787
23. Halgren RG, Traynor AE, Pillay S et al (1998) 8Cl-cAMP cytotoxicity in both steroid sensitive and insensitive multiple myeloma cell lines is mediated by 8Cl-adenosine. Blood 92: 2893-2898 (Pubitemid 28469104)
24. Zhu B, Zhang LH, Zhao YM, Cui JR, Strada SJ (2006) 8-chloro-adenosine induced HL-60 cell growth inhibition, differentiation, and G(0)/G(1) arrest involves attenuated cyclin D1 and telomerase and up-regulated p21 (WAF1/CIP1). J Cell Biochem 97:166-177 (Pubitemid 43050188)
25. Carlson CC, Chinery R, Burnham LL, Dransfield DT (2000) 8-Cl-adenosine-induced inhibition of colorectal cancer growth in vitro and in vivo. Neoplasia 2441-2448
26. Zhang HY, Gu YY, Li ZG et al (2004) Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe. Neoplasia 6:802-812
27. Stellrecht CM, Rodriguez CO Jr, Ayres M, Gandhi V (2003) RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res 63:7968-7974
28. Chen LS, Sheppard TL (2004) Chain termination and inhibition of Saccharomyces cerevisiae poly(A) polymerase by C-8-modified ATP analogs. J Biol Chem 27940405-27940411
29. Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V (2007) Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res 67:9913-9920. doi:10.1158/0008-5472.CAN-07-0770
30. Keyomarsi K, Pardee AB (1993) Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 90:1112-1116 (Pubitemid 23053961)
31. Keyomarsi K, O'Leary N, Molnar G et al (1994) Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54: 380-385 (Pubitemid 24053173)
32. Reed SI (2005) Deregulation of cyclin E in cancer. In: Reed SI (ed) The ubiquitin proteasome system: roles and targets in cancer AACR educational book, American Association for Cancer Research, Philadelphia, pp 53-56
33. Keck JM, Summers MK, Tedesco D et al (2007) Cyclin E overexpression impairs progression through mitosis by inhibiting APCCdh1. J Cell Biol 178:371-385 (Pubitemid 47196147)
34. Akli S, Zheng PJ, Multani AS et al (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64:3198-3208 (Pubitemid 38581423)
35. Ekholm-Reed S, Méndez J, Tedesco D et al (2004) Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol 165:789-800 (Pubitemid 38821970)
36. Bagheri-Yarmand R, Keyomarsi K (2009) Overexpression of full length or low molecular weight of cyclin E leads to differential G2/M transition and mitotic defects through deregulation of cdc25c. AACR Meet Abstr 2009:2473
37. Keyomarsi K, Tucker SL, Buchholz TA et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566-1575 (Pubitemid 35315837)
38. Sieuwerts AM, Look MP, Meijer-van Gelder ME et al (2006) Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 12:3319-3328
39. Keyomarsi K, Tucker SL, Bedrosian I (2003) Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med 9:1.52 (Pubitemid 36227704)
40. Wingate H, Bedrosian I, AkIi S, Keyomarsi K (2003) The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell cycle 2461-2466
41. Wingate H, Zhang N, McGarhen MJ et al (2005) The tumorspecific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280:15148-15157 (Pubitemid 40562869)
42. Akli S, Van Pelt CS, Bui T et al (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67:7212-7222 (Pubitemid 47206549)
43. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM (1996) Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 10:1979-1990 (Pubitemid 26346107)
44. Hapke DM, Stegmann AP, Mitchell BS (1996) Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 56:2343-2347
45. Arner ES, Eriksson S (1995) Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67:155-186
46. Shedden K, Townsend LB, Drach JC, Rosania GR (2003) A rational approach to personalized anticancer therapy: chemoinformatic analysis reveals mechanistic gene-drug associations. Pharm Res 20: 843-847 (Pubitemid 36628428)
47. Carlson CC, Burnham LL, Shanks RA, Dransfield DT (2001) 8-Cl-adenosine induces differentiation in LS174T cells. Dig Dis Sci 46:757-764 (Pubitemid 32373093)
48. Van Loikeren Campagne MM, Villalba Diaz F, Jastorff B, Kessin RH (1991) 8-Chloroadenosine 3′, 5′-monophosphate inhibits the growth of Chinese hamster ovary and Molt-4 cells through its adenosine metabolite. Cancer Res 51:1600-1605
49. Lu X, Errington J, Chen VJ et al (2001) Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clin Cancer Res 6:271-277 (Pubitemid 30065002)
50. Jang JY, Choi Y, Jeon YK, Kim CW (2008) Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res 10:R11
51. Akli S, Keyomarsi K (2003) Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2:S38-S47
52. Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401:297-300 (Pubitemid 129515546)
53. Ma Y, Fiering S, Black C et al (2007) Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci USA 104:4089-4094 (Pubitemid 47181583)
54. Sgambato A, Camermi. A, Pani G et al. (2003) Increased expression of cyclin E is associated with an increased resistance to doxorubicin in rat fibroblasts. Br J Cancer 88:1956-1962 (Pubitemid 36829674)